Interleukin-15 (IL-15) is a recently discovered cytokine that shares with interleukin-2 (IL-2) the beta and gamma subunits of the receptor complex, therefore, both of them display similar biological effects. Moreover, IL-15 induces B and T cell proliferation, natural killer cell cytolytic activity and cytokine generation as well as protects T cell from apoptosis. The IL-15 synthesis and secretion are controlled both at transcriptional and post-transcriptional levels. This fine regulation poses a serious difficulty for its expression in eukaryotic systems. Here, the cDNA of human IL-15 was cloned into a prokaryotic vector under control of the tryptophan promoter for its expression in *Escherichia coli*. The recombinant IL-15 was obtained as an insoluble product, which represented 10% of the total protein. An extraction step in 8 M urea followed by a renaturalization process by diluting urea to 0.08 M was performed. The biological activity of this protein was $2.3 \times 10^5$ IU/mg in a CTLL-2 proliferation assay. The IL-15 proliferative activity on these cells was neutralized by a monoclonal antibody specific to IL-15, showing that the displayed activity was dependent on this cytokine. These simple and fast procedures allowed us to obtain a recombinant human IL-15 in *E. coli*, making this cytokine easily available for in vitro and therapeutic studies.

Keywords: cytokine, eukaryotic system, expression, IL-15, recombinant *E. coli*

**RESUMEN**

Obtención de IL-15 biológicamente activa en *Escherichia coli*. La interleucina-15 (IL-15) es una citocina descrita recientemente que comparte con la IL-2 las subunidades beta y gamma del complejo receptor, y muestra muchos de los efectos biológicos descritos para la IL-2. La IL-15 induce la proliferación de células T, la maduración de células B, la citotoxicidad por células NK y la generación de citocinas, además de proteger a las células T de la apoptosis. La síntesis y secreción de la IL-15 es controlada a nivel transcripcional y post-transcripcional. Esta fuerte regulación representa una dificultad para su obtención biotecnológica en sistemas eucariontes. En este trabajo el ADNc de IL-15 humana fue clonado en un vector para su expresión en *Escherichia coli* bajo el control del promotor triptófano. La proteína fue expresada en forma insoluble y representó el 10% de la proteína total. Se realizó un proceso de extracción con 8 M de urea y de renaturalización por dilución hasta 0.08 M de urea. En el ensayo de proliferación con la línea celular CTLL-2 dependiente de citocinas, la proteína renaturalizada mostró una actividad específica de $2.3 \times 10^5$ UI/mg. La actividad proliferativa sobre estas células fue neutralizada mediante el uso de un anticuerpo monoclonal específico contra IL-15, muestra de que la actividad obtenida es dependiente de esta citocina. La obtención de la IL-15 humana recombinante en *E. coli* por un procedimiento sencillo permite disponer de esta citocina tanto para estudios *in vitro* como para su uso terapéutico.

**Palabras claves:** citocina, *E. coli* recombinante, expresión, IL-15, sistema eucarionte
Alicia Santos et al.

Obtaining biological active IL-15 in E. coli

A neutralizing monoclonal antibody (MAb) to human IL-15 completely inhibited the proliferative activity induced by this bacterially expressed IL-15.

Materials and Methods

Monocyte preparation

PBMCs from healthy volunteers were obtained by Ficoll-Hypaque (Pharmacia, UK) gradient centrifugation after informed consent was received. Monocytes were purified by Percoll gradient. Cells were cultured in RPMI 1640 (Gibco-BRL, USA) containing 2 mM L-glutamine and 10% heat inactivated fetal bovine serum, in presence of 5 µg/mL of LPS, for 6 h at 37 °C and 5% CO₂.

Reverse transcription-polymerase chain reaction (RT-PCR)

Total RNA was purified with TriReagent (Sigma, USA) as specified by the manufacturer’s instructions. cDNA synthesis was performed with 1 µg of total RNA from activated monocyte in a 20-µL volume reaction, containing 50 mmol/L Tris-HCl (pH 8.3), 75 mmol/L KCl, 3 mmol/L MgCl₂, 40 U of RNase inhibitor, 0.1 mg oligo (dT), and 20 U AMV reverse transcriptase (Promega, USA). The reaction mixture was incubated at 42 °C for 1 h and stopped at 90 °C for 5 min. A 3-µL aliquot of the obtained cDNA was amplified by PCR in a 50-µL reaction: 500 mmol/L KCl, 100 mmol/L Tris-HCl buffer (pH 8.8), 25 mmol/L MgCl₂, 2 µmol/L of each dNTP, 25 pmol of each primer, and 5 U Taq DNA polymerase (Enzibiot, Cuba).

The following oligonucleotides were used in the PCRs: IL-15 sense 5’CATGCCATGGCAAACT and 5’U Taq DNA polymerase (Enzibiot, Cuba).

Protein purification

E. coli strains W3110, TG-1 and M-15 containing the pIL1511 vector were grown overnight at 37 °C in 5 mL Luria broth (LB) medium (tryptone 10 g/L, yeast extract 5 g/L, NaCl 10 g/L). Later, 500 µL were taken to inoculate 50 mL of enriched M9 medium (NaHPO₄ 6 g/L, KH₂PO₄ 3 g/L, NaCl 0.5 g/L, NH₄Cl 1 g/L, MgSO₄ 1 mM, CaCl₂ 10 mM, glucose 0.2%, cassein hydrolysat 2%) and further incubated for 2 h at 37 °C. Then, the induction was performed during 12 h at 37 °C in presence of β3-indolacrylic acid (40 µg/mL) for 12 h.

Antibodies and cytokine

Human recombinant IL-15 (WHO Standard Reference Number 95/554, NIBSC, UK) was used as an international standard (10 000 IU/mL), and the MAb to IL-15 (MAB247, IgG1, 0.1 mg/mL; R&D, USA), as a neutralizing antibody in the proliferative assay. Human recombinant IL-15 (20 ng/mL; R&D, USA) was used for Western blot analysis.

Western blot analysis

For Western blot analysis a 15% sodium dodecy sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was resolved with 20 µg of each sample per well, and transferred into Hybond-C membrane in a semi-dry transfer system (Bio-Rad, USA) [13]. The membrane with the transferred proteins was incubated overnight at 4 °C with phosphate-buffered saline (PBS, 0.1 M NaCl, 2 mM KCl, 10 mM Na₂HPO₄, 1 mM KH₂PO₄, pH 7.2) containing 5% skim milk. The membrane was incubated using anti-IL-15 MAb (MAB247) (1 µg/mL) as the primary antibody for 1 h at 37 °C, then washed several times (5 min each) with PBS. Specific antibodies bound to protein bands were detected with an anti-mouse peroxidase conjugate diluted 1:2000 by enhanced chemoluminescence (ECL, Amersham Pharmacia Biotech, UK) according to manufacturer’s instructions.

Bacterial strains

W3110: F- thyA36 deoC2 IN(rrnD-rrnE)1 rph pyrE lambda
TG-1: F' traD36 proAB lac82ZDM15 thi Δ(lac-proAB) supE hisD5
M-15: F- Naf' Str' rif' lac- ara- gal- mtl- recA4
MC1061: F- araD139 Δ ara-leu7696 galU galK Δ(lac)X74 rpsL (Str') thi

Cloning and expression

The amplified gene was ligated into the vector pIL-2 [10] digested with Ncol-BamHI restriction enzyme (Promega, USA) replacing IL-2 gene, under the control of the tryptophan promoter, using ampicillin resistance gene. Ligation were transformed into E. coli strain MC1061 [11]. The recombinant clones were selected by restriction analysis and DNA sequencing [12]. The clone selected was named pIL1511.
Proliferation assay

CTLL-2 is a cytokine-dependent murine T-cell line which proliferates in response to human IL-15 [6]. The bioassay was performed in a 96-well cell culture cluster dish (Costar, USA) at 5 x 10^3 CTLL-2 cells per well, previously washed three times with medium without serum, and incubated in presence of twofold serial dilutions (starting dilution 1:1000) of recombinant human IL-15 international standard and the IL-15 obtained from the renaturalization process in 100 µL total volume at 37 °C and 5% CO₂. After 48 h 1-[4,5-dimethylthiazol-2-g1]-3,5 diphenylformazan (MTT) [16] was added and the plates were further incubated for 4 h. Finally, 50 µL of a solution containing 10% SDS, 0.1N HCL and 50% isopropylalcohol were added per well. Plates were read at 570 nm on a Multiscan (Sensident Scan, Merck, Germany). Regression, parallelism and lineality of the results were analyzed by the exact Fisher’s test.

The specific activity was calculated by the ratio of activity determined by CTLL-2 assay and the protein concentration of recombinant product of SephadexG-25 chromatography.

Results and Discussion

To clone the mature region of human IL-15, cDNA from LPS-induced PBMC was amplified by PCR with specific primers containing the end restriction site, the methionine codon as initiation of translation site and the stop codon. The amplified product was purified from gel and cloned into the pIL-2 vector, under control of the tryptophan promoter (Figure 1).

To compare the expression levels, the IL-15 gene was expressed in three different E. coli strains (W3110, TG-1 and M-15). Cells induced during 12 h were collected and analyzed by SDS-PAGE. Similar expression levels (about 10% of total cellular protein) were observed in all strains (Figure 2A). The expression of the IL-15 heterologous product was confirmed by immunodetection using a specific MAb (Figure 2B).

Cells were disrupted and IL-15 protein was found in the insoluble fraction (Figure 3). The cellular pellet was consecutively washed with TE and 3 M urea, and the protein was completely extracted in 8 M urea. Protein yield was not affected after washing (Figure 4A). After a renaturalization process, a single band at 12.5 kD using SDS-PAGE followed by Coomassie blue staining and densitometry in gel electrophoresis, confirmed that IL-15 was the dominant protein in the preparation with 90% purity (Figure 4B).
Using as a reference an international standard of IL-15, this fraction was tested on CTLL-2 cell line in order to determine the proliferative activity. As shown in Figure 5, the IL-15 obtained using this procedure induces the proliferation of CTLL-2 cell line in a dose-dependent manner with an specific activity of $2.3 \times 10^5$ IU/mg. Fisher’s exact statistical test showed linearity and parallelism ($P > 0.05$), and the regression was highly significant ($P < 0.01$). Therefore, during the renaturalization process IL-15 is obtained in a correct functional conformation.

To demonstrate the specificity of the biological effect in the extract, a neutralizing MAb to human IL-15 at 0.1 mg/mL was used, and it was observed that the proliferative response was totally inhibited in presence of this antibody.

Thus, it was demonstrated the feasibility of the *E. coli* bacterial system to express a complex eukaryotic protein, such as IL-15, in its biologically active form. No toxic effects were observed in bacteria, at least 12 h after induction. Finally, the addition of an N-terminal methionine and the lack of glycosylation, two of the principal disadvantages of this system [17], did not affect the *in vitro* biological activity of the IL-15 expressed in *E. coli*.

Received in December, 1999. Accepted for publication in August, 2000.

---

Figure 5. Induction of CTLL-2 proliferation by IL-15 preparation. CTLL-2 cells were incubated with serial dilutions of an international standard of IL-15 and IL-15 obtained from *E. coli* initially diluted to $10^3$ and in presence of the neutralizing monoclonal antibody to human IL-15, during 48 h at 37°C, and 5% CO₂. Proliferation was measured by MTT colorimetric assay. Fisher’s exact test showed significant levels of 0.0001, 0.3150, and 0.2953 for regression, parallelism and linearity, respectively.